Cordasco Financial Network lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 20.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,770 shares of the company’s stock after purchasing an additional 4,335 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.5% of Cordasco Financial Network’s portfolio, making the stock its 8th largest position. Cordasco Financial Network’s holdings in Merck & Co., Inc. were worth $1,450,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Krilogy Financial LLC lifted its position in Merck & Co., Inc. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock worth $201,000 after buying an additional 11 shares during the last quarter. Balentine LLC lifted its position in Merck & Co., Inc. by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after buying an additional 20 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in Merck & Co., Inc. by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 9,291 shares of the company’s stock worth $595,000 after buying an additional 39 shares during the last quarter. Thompson Davis & CO. Inc. lifted its position in Merck & Co., Inc. by 0.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock worth $276,000 after buying an additional 40 shares during the last quarter. Finally, Cornerstone Advisory LLP lifted its position in Merck & Co., Inc. by 0.4% in the 2nd quarter. Cornerstone Advisory LLP now owns 11,110 shares of the company’s stock worth $712,000 after buying an additional 43 shares during the last quarter. 72.65% of the stock is owned by institutional investors.
Shares of Merck & Co., Inc. (NYSE MRK) opened at $54.87 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Co., Inc. has a 12-month low of $53.36 and a 12-month high of $66.80. The firm has a market capitalization of $149,490.00, a P/E ratio of 29.19, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be issued a dividend of $0.48 per share. The ex-dividend date is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.50%. Merck & Co., Inc.’s dividend payout ratio is presently 102.13%.
Merck & Co., Inc. declared that its Board of Directors has approved a share repurchase plan on Tuesday, November 28th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
A number of research firms recently weighed in on MRK. JPMorgan Chase & Co. set a $70.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Sunday, October 29th. Berenberg Bank restated a “hold” rating on shares of Merck & Co., Inc. in a research report on Wednesday, November 1st. Bank of America began coverage on Merck & Co., Inc. in a research report on Tuesday, November 28th. They issued a “buy” rating and a $64.00 target price for the company. ValuEngine downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Morgan Stanley boosted their target price on Merck & Co., Inc. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company. Merck & Co., Inc. currently has a consensus rating of “Hold” and an average target price of $66.35.
In related news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $53.57, for a total transaction of $267,850.00. Following the completion of the transaction, the director now owns 5,100 shares in the company, valued at $273,207. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total value of $3,697,800.00. Following the transaction, the insider now owns 101,484 shares of the company’s stock, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,500 shares of company stock valued at $5,026,025. 0.25% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3222833/cordasco-financial-network-raises-stake-in-merck-co-inc-mrk.html.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.